Vericel Corp (VCEL) Stock Price & Analysis
Vericel Corp (VCEL) rose 0.01% to USD 45.05 as of July 25, 2026 at 11:15 UTC, according to Nexqual real-time market data.
VCEL last closed at USD 45.05; the session ranged USD 44.69–46.15 on volume of 339,414 shares. Market capitalization is $2.30B, with a 52-week range of USD 28.95–48.75 (NGM). Source: Nexqual, July 25, 2026 at 11:15 UTC.
Key Statistics (as of July 25, 2026 at 11:15 UTC)
| Price | USD 45.05 |
|---|---|
| Change | ▲ 0.01% (up) |
| Previous Close | USD 45.05 |
| Open | USD 46.15 |
| Day Range | USD 44.69 – 46.15 |
| 52-Week Range | USD 28.95 – 48.75 |
| Volume | 339,414 shares |
| Market Cap | $2.30B |
| Exchange | NGM |
Technical Analysis (VCEL)
Nexqual's technical model rates VCEL "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 11:15 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 55.26 (neutral) |
| vs SMA50 | Above (USD 40.35) |
| MACD | 1.35 (positive) |
Analyst Ratings (VCEL)
Wall Street analysts rate VCEL "Strong Buy" based on 7 analysts, with a mean price target of USD 57.14 (range USD 46–70), per Nexqual as of July 25, 2026 at 11:15 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 57.14 |
| High Target | USD 70 |
| Low Target | USD 46 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (VCEL)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD -0.03 |
| Revenue Estimate | $72.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.12 vs est -0.16 ▲ beat |
| 2025-12-31 | USD 0.45 vs est 0.38 ▲ beat |
| 2025-09-30 | USD 0.1 vs est -0.01 ▲ beat |
| 2025-06-30 | USD -0.01 vs est -0.04 ▲ beat |
Source: Nexqual, July 25, 2026 at 11:15 UTC.
Financials & Fundamentals (VCEL)
| Total Revenue | $292.09M |
|---|---|
| Revenue Growth (YoY) | +30.10% |
| Gross Margin | +74.84% |
| Operating Margin | -11.79% |
| Profit Margin | +7.35% |
| ROE | +6.59% |
| Debt / Equity | 26.68 |
| Current Ratio | 5.18 |
| Total Cash | $145.34M |
| Total Debt | $95.04M |
| Free Cash Flow | $42.37M |
Source: Nexqual, July 25, 2026 at 11:15 UTC.
Financial Health Score (VCEL)
Nexqual rates Vericel Corp's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 11:15 UTC.
| Growth | Strong — Revenue +16% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 75%, operating -12% |
| Balance Sheet | Strong — $145M cash vs $95M debt, net cash position |
| Cash Flow | Strong — FCF $42M, 15% margin |
| Efficiency | Mixed — ROE 7%, ROA 2.2% |
Ownership (VCEL)
| Insider Ownership | +1.19% |
|---|---|
| Institutional Ownership | +112.99% |
| Shares Outstanding | 51.07M |
| Float | 50.44M |
| Short % of Float | +11.62% |
Source: Nexqual, July 25, 2026 at 11:15 UTC.
Leadership (VCEL)
Vericel Corp is led by Dominick C. Colangelo (age 61), CEO, President & Director, per Nexqual as of July 25, 2026 at 11:15 UTC.
| CEO, President & Director | Dominick C. Colangelo (age 61) |
|---|---|
| CFO & Treasurer | Joseph Anthony Mara (age 49) |
| Chief Operating Officer | Michael Halpin (age 63) |
| Vice President of Finance & Investor Relations | Eric Burns |
| Chief Marketing Officer | Roland DeAngelis |
Major Backers & Investors (VCEL)
Notable institutional backers of Vericel Corp include Congress Asset Management Co, Soleus Capital Management, L.P., Conestoga Capital Advisors, LLC, according to Nexqual as of July 25, 2026 at 11:15 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Congress Asset Management Co | 5.71% |
| Soleus Capital Management, L.P. | 4.99% |
| Conestoga Capital Advisors, LLC | 4.82% |
| William Blair Investment Management, LLC | 3.59% |
| BNP Paribas Asset Management Holding S.A. | 3.38% |
| Geneva Capital Management LLC | 3.22% |
| GW&K Investment Management, LLC | 3.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.56% |
| Vanguard Group | 8.63% |
| State Street | 8.5% |
Source: Nexqual, July 25, 2026 at 11:15 UTC.
From Vericel Corp's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
- Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XNCR | Xencor, Inc. | USD 19.44 | ▼ 0.36% |
| VCYT | Veracyte, Inc. | USD 56.61 | ▼ 2.41% |
| PTCT | PTC Therapeutics, Inc. | USD 76.82 | ▼ 2.02% |
| SNDX | Syndax Pharmaceuticals, Inc. | USD 20.81 | ▼ 5.62% |
| RGNX | REGENXBIO Inc. | USD 9.73 | ▼ 4.61% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 11:15 UTC. This page is informational and not investment advice.